Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Next Previous
Trial Profile

First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HemaXellerate I (Primary)
  • Indications Bone marrow disorders
  • Focus Adverse reactions; First in man; Proof of concept

    • Most Recent Events

    • 24 Oct 2016 Final clinical data on their first 5 patients published in Regen BioPharma media release.
    • 16 Aug 2016 Updated interim results (n=5) published in a Regen BioPharma Inc media release.
    • 11 May 2016 According to Regen media release, the Company intends to amend its previously submitted Investigational New Drug Application for HemaXellerate in order that Regen may obtain consent from the United States Food and Drug Administration (FDA) to pursue this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top